疏血通注射液安全性证据体的构建

证据体是由多种研究方法、多种来源的证据构成。疏血通注射液作为中药注射剂的一种,与其他中药注射剂相同,其安全性倍受医务人员关注,而目前关于疏血通安全性的证据较为零散、缺乏系统性。为构建疏血通注射液安全性证据体,继而为临床及科研提供数据支持。该文通过检索疏血通安全性相关的期刊文献的方式,收集疏血通注射液安全性相关证据并予以分类。结果长期、大样本、前瞻性的医院集中监测研究证据强度较大,医院信息系统数据分析、国家自发呈报系统数据分析的证据强度次之,系统评价报告的不良反应、不良反应个案分析的证据强度较弱。因此,基于现有证据,证明疏血通注射液具有较好的安全性,其不良反应多为过敏反应,且好发于老年人,而未将证据分级是本研究的局限。

Building safety evidence body of Shuxuetong injection

Evidence body is defined as an evidence complex incorporating the evidence obtained from various research methods and various resources.As one of common parenterally administered Chinese medicines, Shuxuetong's safety drew high concern from doctors.However, we only have grasped several but less systematic evidence on the safety of Shuxuetong. To build a safety evidence body of Shuxuetong injection. Review and evaluate the evidence related to the safety of Shuxuetong injection after accumulating, searching and classfyingrelated literature. Accoeding to levels of evidence from high to low, the evidence related to the safety of Shuxuetong injection was classified as following: the evidence from a long-term, prospective, large-sample-size and intensive hospital monitoring study was the strongest; the evidence of hospital information system (HIS) data analysis; the evidence of spontaneous reporting system (SRS) data analysis; the evidence of adverse drugreactions (ADRs)/adverse drug events (ADEs) reported in systematic evaluation, ADRs case report, toxicological tests, pharmacological tests were weakest. Based on the evidence body, Shuxuetong Injection was proved to be safe, and its ADRs were mainly allergic reactions, and more often happened among the old patients.